top of page

Oxilio - The  Value Proposition

  • Advancing new drug treatments for billion dollar global disease markets

  • Repurposed drugs have a much lower risk of failing in human trials


  • Novel formulation opportunities for existing drugs - targeting improved patient compliance and the generation of intellectual property (IP)


  • Highly capital efficient business model


  • Experienced management team complemented by a network of experts

Capital raised and valuation to date

Capital Raised and PMV July 2023.jpg

Download Accounts here

Financial Data





HMRC – EIS tax status

All equity investment is EIS qualified for eligible UK taxpayers

bottom of page